SecBot SecBot
SECBOTREPLAY Home › Report › ARGX

ARGX · argenx is acquiring Forte Biosciences for $77/share in cash, total…

argenx SE · PRESS-RELEASE filed Jul 27, 2026 at 01:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jul 27, 2026 at 01:00 ET

argenx is acquiring Forte Biosciences for $77/share in cash, total equity value ~$2.2B, an 86% premium to Forte's VWAP since positive Phase 1b vitiligo data. The deal adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, fitting argenx's strategy to expand its immunology pipeline beyond FcRn blockade. The acquisition is fully funded from cash on hand and expected to close in Q3 2026, with no financing condition, a disciplined bolt-on that broadens argenx's T-cell/NK-cell targeting capability without diluting shareholders.

  • argenx acquires Forte Biosciences for $77/share cash, ~$2.2B total equity value
  • 86% premium to Forte's VWAP since July 9, 2026 positive Phase 1b vitiligo data
  • FB102 is a first-in-class anti-CD122 antibody with Phase 1b proof-of-concept in vitiligo and celiac disease
  • Phase 2 celiac data expected H2 2026; potential in alopecia areata and other autoimmune diseases

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access